A new antibacterial peptide named pentaminomycin C was isolated from an extract of Streptomyces cacaoi subsp. cacaoi NBRC 12748^T, along with a known peptide BE-18257A. Pentaminomycin C was determined to be a cyclic pentapeptide containing an unusual amino acid, Nδ-hydroxyarginine (5-OHArg), by a combination of ESI-MS and NMR analyses. The structure of pentaminomycin C was determined to be cyclo(-L-Leu-D-Val-L-Trp-L-5-OHArg-D-Phe-). Pentaminomycin C exhibited antibacterial activities against Gram-positive bacteria including Micrococcus luteus, Bacillus subtilis, and Staphylococcus aureus. The biosynthetic gene cluster for pentaminomycin C and BE-18257A was identified from the genome sequence data of S. cacaoi subsp. cacaoi.

01 Feb 1998·Journal of UrologyQ1 · MEDICINE

RENAL ACTIONS OF ENDOTHELIN-1 UNDER ENDOTHELIN RECEPTOR BLOCKADE BY BE-18257B

Q1 · MEDICINE

Article

Author: Gulmi, Frederick A. ; Chou, Shyan-Yih ; Syed, Nabeel ; Mooppan, Unni M.M. ; Kim, Hong

PURPOSEEndothelin-1 (ET-1), a peptide produced by the vascular endothelium, causes profound renal vasoconstriction by binding to ET-A receptors. The present study examined the renal actions of ET-1 after ET-A receptors were blocked by BE-18257B to unmask the functions of ET-B receptors.MATERIALS AND METHODSRenal hemodynamics and clearance measurements were obtained in anesthetized dogs after intrarenal infusion of BE-18257B at 100 ng./kg./min. (Group 1), after intrarenal infusion of ET-1 at 2 ng./kg./min. (Group 2), or after intrarenal infusion of ET-1 superimposed on BE-18257B (Group 3).RESULTSIn Group 1, BE-18257B infusion did not alter arterial pressure, renal blood flow (RBF), GFR or tubular function. In Group 2, ET-1 infusion led to a significant decrease in RBF and GFR (37 and 40%, respectively) without altering arterial pressure. Urinary volume and sodium excretion were not changed but osmolality decreased significantly. In Group 3, BE-18257B infusion significantly attenuated the decrease in RBF caused by ET-1 and increased GFR by 40% without altering arterial pressure, associated with significant diuresis and natriuresis.CONCLUSIONRenal vasoconstriction caused by ET-1 is attenuated by ET-A receptor blockade with BE-18257B, which unmasks the hemodynamic and tubular actions of ET-B receptors. As a result, it limits the ET-1 induced decrease in RBF and raises GFR, and leads to a diuresis and natriuresis.

01 Dec 1996·EndocrinologyQ2 · MEDICINE

Combination of insulin-like growth factor (IGF)-I and IGF-binding protein-1 promotes fibroblast-embedded collagen gel contraction.

Q2 · MEDICINE

Article

Author: Y Oshita ; Y R Lee ; R Tsuboi ; H Ogawa

Wound contraction is an important event that minimizes the wound defect during the healing process. Involvement of insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-1 in wound contraction was studied using an in vitro model. Human dermal fibroblasts (1 x 10(5) cells/ml) were incorporated into a porcine type I collagen (0.21% final) in serum-free medium. The fibroblast-embedded collagen gels in a 12-well plate were floated from the well, and various reagents were then added to the assay medium. The surface area of the gel was calculated by measuring the diameters of the collagen gel. IGF-I at high doses (30 and 100 ng/ml) revealed 6.8% (P < 0.01) and 7.7% (P < 0.001) gel contraction, respectively, and des (1-3) IGF-I at 10 ng/ml produced a 4.5% gel contraction (P < 0.01). Meanwhile, IGFBP-I did not induce any significant contraction throughout the tested concentrations (0.1-100 ng/ml). A combination of IGF-I and IGFBP-1 at 1 ng/ml of each reagent, a concentration at which gel contraction was not observed when each of the reagents was tested individually, produced a 14% gel contraction (P < 0.001), whereas combinations of des (1-3) IGF-I with IGFBP-1 at the same concentrations did not promote gel contraction. The increased IGFBP-I doses in combination with 1 ng/ml IGF-I tended to enhance the gel contraction. IGF-I- and IGFBP-1-induced gel contraction was prominent during the initial 12-h incubation period. When anti-IGF-I, anti-IGFBP-1, or anti-IGF-I receptor antibody was added to the assay medium before the addition of IGF-I and IGFBP-1, the IGF-I- and IGFBP-1-induced gel contraction was significantly suppressed (P < 0.001). Endothelin-1, a vasoconstrictor peptide that is known to promote fibroblast-embedded collagen gel contraction, appeared to be partially involved in the IGF-I- and IGFBP-1-induced gel contraction, because the addition of an endothelin receptor antagonist (Bosentan or BE-18257B at 1 microg/ml) moderately suppressed the IGF-I- and IGFBP-1-induced gel contraction (P < 0.01). On the other hand, when IGF-I and IGFBP-1 were applied with endothelin-1 (1 nM), an enhanced gel contraction (29.4%) was observed that was significantly greater than that induced by either individually (P < 0.001). These results clearly indicate that the combination of IGF-I and IGFBP-1 promotes fibroblast contraction in collagen gel, and that this phenomenon is caused by IGFBP-1's strong potentiation of the IGF-I-induced gel contraction.

100 Deals associated with BE-18257B

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Discovery	JP	MSD (Japan) Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

BE-18257B

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation